Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(01): 084-094
DOI: 10.1055/s-0041-1735650
Review Article

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis

Satya Pal Kataria
1   Department of Medical Oncology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
,
Mukesh Nagar
1   Department of Medical Oncology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
,
Shikha Verma
2   Department of Oncology, Lupin Ltd., Mumbai, Maharashtra, India
,
Vinay Purohit
2   Department of Oncology, Lupin Ltd., Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Shikha Verma

Background Systemic fluoropyrimidines, both oral and intravenous, are an integral part of colorectal cancer (CRC) management. They can be administered either with curative or palliative intent.

Objectives This article examines the literature to analyze the efficacy and safety of the oral fixed-dose combination of uracil and tegafur (UFT)/leucovorin (LV) compared with other fluoropyrimidine agents, with an intention to implement the findings into the current treatment algorithms for CRC.

Methods An exhaustive systematic literature search was performed for prospective studies using PUBMED, Cochrane Library, and EMBASE database. Studies which met eligibility criteria were shortlisted and grouped into chemotherapy given for curative or palliative intent.

Results Eight trials were shortlisted involving 4,486 patients for the analysis. There was no difference between UFT/LV and other fluoropyrimidines in the primary endpoints—disease-free survival (hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.90–.15; p = 0.81) and progression-free survival (HR 0.87; 95% CI 0.66–.66; p = 0.35) for curative and palliative intent CRC patients, respectively. In secondary analyses, there was no significant difference observed between UFT and other fluoropyrimidines in overall survival in CRC patients with curative intent (HR 1.04; 95% CI 0.88–1.23; p = 0.63) and palliative intent (HR 1.02; 95% CI 0.97–1.06; p = 0.42) . In the safety analysis, we found significantly lesser patients on UFT/LV had stomatitis/mucositis (odds ratio [OR] 0.20; 95% CI 0.05–0.85; p = 0.03), fever (OR 0.46; 95% CI 0.29–0.71; p < 0.001), infection (OR 0.42; 95% CI 0.24–0.74; p < 0.01), leukopenia (OR 0.04; 95% CI 0.00–0.95; p = 0.05), febrile neutropenia (OR 0.03; 95% CI 0.00–0.24; p = 0.001), and thrombocytopenia (OR 0.14; 95% CI 0.02–0.79; p = 0.03) compared with other fluoropyrimidines.

Conclusion Oral UFT/LV is equally efficacious to other fluoropyrimidines, especially intravenous 5-fluorouracil, in the management of early as well as advanced CRC patients. Importantly, UFT/LV has a superior safety profile compared with other fluoropyrimidines in terms of both hematological and nonhematological adverse events.

Keywords

uracil-tegafur - colorectal cancer - 5-fluorouracil - meta-analysis - systematic review

Earlier Presentation

None.


Supplementary Material



Publication History

Article published online:
02 February 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2018
    Google Scholar
  • 2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313] CA Cancer J Clin 2018; 68 (06) 394-424
    Google Scholar
  • 3 Snaebjornsson P, Jonasson L, Olafsdottir EJ. et al. Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years. Int J Cancer 2017; 141 (03) 531-539
    CrossrefPubMedGoogle Scholar
  • 4 National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer (Version 4. 2020). Accessed September 01, 2020 at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
    Google Scholar
  • 5 National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer (Version 6. 2020). Accessed September 01, 2020 at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
    Google Scholar
  • 6 Schilsky RL. Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer 2002; 2 (01) 51-52
    CrossrefPubMedGoogle Scholar
  • 7 Waxman S, Bruckner H. The enhancement of 5-fluorouracil anti-metabolic activity by leucovorin, menadione and alpha-tocopherol. Eur J Cancer Clin Oncol 1982; 18 (07) 685-692
    CrossrefPubMedGoogle Scholar
  • 8 Rustum YM. Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. J Chemother 1990; 2 (Suppl. 01) 5-11
    CrossrefPubMedGoogle Scholar
  • 9 Machover D, Schwarzenberg L, Goldschmidt E. et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 1982; 66 (10) 1803-1807
    Google Scholar
  • 10 Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000; 18 (04) 331-342
    CrossrefPubMedGoogle Scholar
  • 11 Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15 (01) 110-115
    CrossrefPubMedGoogle Scholar
  • 12 Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17 (02) 239-245
    CrossrefPubMedGoogle Scholar
  • 13 Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S. National Surgical Adjuvant Study of Colorectal Cancer. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36 (04) 237-244
    CrossrefPubMedGoogle Scholar
  • 14 Central Drugs Standard Control Organisation. Ministry of Health & Family Welfare, Directorate General of Health Services, Government of India. Accessed September 01, 2020 at: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/dciApprovedfdc.pdf
    Google Scholar
  • 15 Bin Q, Li J, Liao C, Cao Y, Gao F. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. Colorectal Dis 2011; 13 (08) 837-845
    CrossrefPubMedGoogle Scholar
  • 16 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017; 7 (07) CD008398
    PubMedGoogle Scholar
  • 17 Shimada Y, Hamaguchi T, Mizusawa J. et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer 2014; 50 (13) 2231-2240
    CrossrefPubMedGoogle Scholar
  • 18 Kroep JR, van Werkhoven E, Polee M. et al. Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer–TLC study. J Geriatr Oncol 2015; 6 (04) 307-315
    CrossrefPubMedGoogle Scholar
  • 19 Chen J, Wang J, Xu T. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (30) e16667
    CrossrefPubMedGoogle Scholar
  • 20 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. [published correction appears in Int J Surg. 2010;8(8):658] Int J Surg 2010; 8 (05) 336-341
    CrossrefPubMedGoogle Scholar
  • 21 Higgins JPT, Thomas J, Chandler J. et al , eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed.. Chichester, UK: John Wiley & Sons; 2019
    CrossrefGoogle Scholar
  • 22 Trotti A, Colevas AD, Setser A. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13 (03) 176-181
    CrossrefPubMedGoogle Scholar
  • 23 Eisenhauer EA, Therasse P, Bogaerts J. et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedGoogle Scholar
  • 24 Oken MM, Creech RH, Tormey DC. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
    Google Scholar
  • 25 Higgins JP, Altman DG, Gøtzsche PC. et al; Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    Google Scholar
  • 26 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 27 Kim DJ, Kim TI, Suh JH. et al. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. Yonsei Med J 2003; 44 (04) 665-675
    CrossrefPubMedGoogle Scholar
  • 28 Lembersky BC, Wieand HS, Petrelli NJ. et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24 (13) 2059-2064
    CrossrefPubMedGoogle Scholar
  • 29 de la Torre A, García-Berrocal MI, Arias F. et al. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Biol Phys 2008; 70 (01) 102-110
    CrossrefPubMedGoogle Scholar
  • 30 Douillard JY, Hoff PM, Skillings JR. et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20 (17) 3605-3616
    CrossrefPubMedGoogle Scholar
  • 31 Carmichael J, Popiela T, Radstone D. et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20 (17) 3617-3627
    CrossrefPubMedGoogle Scholar
  • 32 Nogué M, Salud A, Batiste-Alentorn E. et al. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer 2005; 41 (15) 2241-2249
    CrossrefPubMedGoogle Scholar
  • 33 Grage TB, Moss SE. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial. Surg Clin North Am 1981; 61 (06) 1321-1329
    CrossrefPubMedGoogle Scholar
  • 34 Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370 (9604): 2020-2029
    CrossrefPubMedGoogle Scholar
  • 35 Bosset JF, Collette L, Calais G. et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. [published correction appears in N Engl J Med. 2007 Aug 16;357(7):728] N Engl J Med 2006; 355 (11) 1114-1123
    CrossrefPubMedGoogle Scholar
  • 36 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10) 1215-1223
    CrossrefPubMedGoogle Scholar
  • 37 Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10 (06) 904-911
    CrossrefPubMedGoogle Scholar
  • 38 Baratelli C, Zichi C, Di Maio M. et al. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Crit Rev Oncol Hematol 2018; 122: 21-29
    CrossrefPubMedGoogle Scholar
  • 39 Meulendijks D, Henricks LM, Jacobs BAW. et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 2017; 116 (11) 1415-1424
    CrossrefPubMedGoogle Scholar
  • 40 Delea TE, Vera-Llonch M, Edelsberg JS. et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 2002; 5 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 41 Yonekura K, Basaki Y, Chikahisa L. et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5 (08) 2185-2191
    PubMedGoogle Scholar
  • 42 Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel) 2018; 6 (02) 31
    Google Scholar